HolderBook

Velan Capital Investment Management LP

Reported holdings as of Q2 2026, from 19 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1848809
Reported value
$164.2M
Positions
50
Top 10 weight
75.4%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
PRAXIS PRECISION MEDICINES IPRAX$29.7M88,78118.10%-2.24pp11q-11.9%-$4.0M
MAPLIGHT THERAPEUTICS INCMPLT$17.7M492,89310.76%+4.48pp3qHELD
SUTRO BIOPHARMA INCSTRO$17.0M512,16010.36%+2.36pp3qHELD
IMMIX BIOPHARMA INCIMMX$11.2M1,085,0006.81%+2.59pp5q+46.6%+$3.6M
PROTARA THERAPEUTICS INCTARA$10.9M2,844,6526.62%-2.63pp9qHELD
TENAX THERAPEUTICS INC CALLTENX$9.0M549,9855.48%-0.36pp8q-5.7%-$545.8K
ABIVAX SAABVX$8.7M65,6305.33%-0.04pp4q-14.8%-$1.5M
ANTERIS TECHNOLOGIES GLOBALAVR$6.9M700,0004.20%+1.77pp2qHELD
EDESA BIOTECH INCEDSA$6.7M827,5004.10%+1.39pp6qHELD
EVOMMUNE INCEVMN$6.0M451,2553.65%-2.77pp3q+1.1%+$66.5K
AVALO THERAPEUTICS INCAVTX$6.0M324,4523.65%+1.92pp7q+75.3%+$2.6M
XENCOR INCXNCR$4.1M255,0002.50%+0.61pp2q+2.0%+$80.5K
REZOLUTE INCRZLT$3.9M750,0002.38%+0.94pp10qHELD
HERON THERAPEUTICS INCHRTX$3.7M8,753,2902.28%-2.11pp15qHELD
VERRICA PHARMACEUTICALS INCVRCA$2.9M471,5591.76%+0.19pp3qHELD
C4 THERAPEUTICS INCCCCC$2.7M570,0001.62%-newNEW
EUPRAXIA PHARMACEUTICALS INCEPRX$2.3M352,0001.42%-0.18pp4qHELD
ADMA BIOLOGICS INCADMA$2.1M250,0001.27%-newNEW
REIN THERAPEUTICS INCRNTX$1.8M1,700,0001.08%-newNEW
LYELL IMMUNOPHARMA INCLYEL$1.5M105,0000.90%-0.38pp2q+2.9%+$42.1K
NASUS PHARMA LTDNSRX$1.3M359,3900.77%+0.27pp2qHELD
PROFOUND MED CORPPROF$1.1M170,2780.69%-0.47pp3q-40.4%-$767.6K
JASPER THERAPEUTICS INCJSPR$1.1M2,668,3950.68%-0.78pp10qHELD
PROTAGONIST THERAPEUTICS INCPTGX$453.5K3,7000.28%+0.03pp5qHELD
CYTOMX THERAPEUTICS INCCTMX$450.0K120,0000.27%-1.32pp7q-77.8%-$1.6M
NEUMORA THERAPEUTICS INC.NMRA$391.0K230,0000.24%+0.14pp2q+187.5%+$255.0K
NURIX THERAPEUTICS INCNRIX$388.2K16,0000.24%+0.08pp5qHELD
OVID THERAPEUTICS INCOVID$349.7K130,0000.21%-0.01pp7q-18.8%-$80.7K
PRECISION BIOSCIENCES INCDTIL$314.4K40,0000.19%+0.05pp4qHELD
MINERALYS THERAPEUTICS INCMLYS$296.8K11,0000.18%-0.01pp6qHELD
MACROGENICS INCMGNX$277.2K60,0000.17%+0.11pp2q+100.0%+$138.6K
CORBUS PHARMACEUTICALS HLDGSCRBP$243.9K26,0000.15%flat8qHELD
ARTIVA BIOTHERAPEUTICS INCARTV$242.5K25,0000.15%+0.05pp2qHELD
REPLIMUNE GROUP INCREPL$221.4K20,0000.13%+0.04pp7qHELD
SYNDAX PHARMACEUTICALS INCSNDX$218.6K10,0000.13%-0.01pp4qHELD
IMMUNOME INCIMNM$211.9K10,0000.13%-0.01pp4qHELD
TECTONIC THERAPEUTIC INCTECX$206.2K6,0000.13%-newNEW
ROCKET PHARMACEUTICALS INCRCKT$205.2K60,0000.12%-0.54pp2q-79.6%-$802.5K
KARYOPHARM THERAPEUTICS INCKPTI$195.4K20,0000.12%+0.07pp2q+33.3%+$48.9K
AN2 THERAPEUTICS INCANTX$193.6K40,0000.12%-newNEW
VIRIDIAN THERAPEUTICS INCVRDN$183.7K10,0000.11%-1.00pp5q-89.0%-$1.5M
SCYNEXIS INC$162.8K40,0000.10%-newNEW
QUOIN PHARMACEUTICALS LTDQNRX$156.7K32,3720.10%-0.26pp2q-61.8%-$254.0K
XILIO THERAPEUTICS INCXLO$136.8K14,2850.08%+0.01pp2qHELD
INSPIREMD INCNSPR$103.7K148,1380.06%-2.08pp13q-92.9%-$1.4M
KALARIS THERAPEUTICS INCKLRS$101.8K25,0000.06%flat2q+38.9%+$28.5K
LARIMAR THERAPEUTICS INCLRMR$100.7K33,0000.06%-0.03pp7qHELD
PROQR THRAPEUTICS N VPRQR$83.7K45,0000.05%+0.01pp7qHELD
CONTEXT THERAPEUTICS INCCNTX$33.1K59,7000.02%-0.14pp9q-40.3%-$22.3K
GOSSAMER BIO INCGOSS$11.5K70,0000.01%-0.01pp7qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 94.9%Medical Devices 5.0%Not classified 0.1%
 
SectorValueShare
Biotech & Pharma$155.9M94.9%
Medical Devices$8.1M5.0%
Not classified$162.8K0.1%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+6.4%+14.8%-8.4%100%
Q1 2026+1.0%-4.6%+5.6%84%
Q4 2025+79.2%+2.4%+76.8%100%
Q3 2025+31.1%+7.8%+23.3%100%
Q2 2025+7.0%+10.5%-3.4%91%
Q1 2025-31.9%-4.6%-27.3%100%
Q4 2024+7.1%+2.1%+5.0%98%
Q2 2024+4.1%+4.0%+0.1%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$164.2M506911575.4%45
Q1 2026$159.6M4912127973.1%45
Q4 2025$172.4M469551271.0%44
Q3 2025$106.5M49111451268.2%45
Q2 2025$101.2M5010165769.3%45
Q1 2025$97.2M4710162876.7%45
Q4 2024$115.9M453242586.6%45
Q3 2024$106.9M18623592.2%45
Q2 2024$174.6M17522995.5%45
Q1 2024$220.2M21823790.3%44
Q4 2023$171.3M207311588.2%45
Q3 2023$124.0M28445678.2%44
Q2 2023$107.7M30794866.2%42
Q1 2023$117.3M3114521177.5%45
Q4 2022$113.2M281234880.0%44
Q3 2022$100.8M24764684.9%45
Q2 2022$98.6M23663686.9%46
Q1 2022$107.8M23443879.9%46
Q4 2021$128.9M27000077.3%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.